Get Flat 15% Discount on ED Drugs for orders value $70 or more
  • Danielle Jolla, United States says, "I love your online pharmacy Because of your quick shipping and reasonable prices."
  • Jill Barrella, United States says, "Seemed easy to purchase, reasonable prices. Good customer service when I used it."
  • Brian Pavey, United States says, "I am very satisfied with IDM and plan on making more purchases in the future. IDMs prices are low which makes it very compelling to use over conventional pharmacies with high copays and more restrictions continually implemented."
  • Eric Gonzales, United States says, "The website is very user friendly, there is a lot of variety and checking out was easy."
  • Albert Martinez, United States says, "Very organized and efficient concerning delivery and products are great. Very satisfied, impressed with delivery and product."
  • Natalie Wallace, United States says, "I absolutely love getting my medications at a great price and I always get that here. And I recommend this site to my family and friends."
  • Ask our pharmacist, if you have any questions related to your medications
    Click to find International Shipping charges at our pharmacy.
    Shop & Earn @ InternationalDrugMart
    Easy and secure shopping @
    Get your instant Coupon now!
    Price challenge
    You can find the latest happening of our pharmacy Visit to discuss on various diseases and conditions
    Follow us on Twitter

      Ranbaxy targets M&A for drugs growth

      Ranbaxy Laboratories Ltd is actively pursuing a handful of acquisition opportunities in the United States and elsewhere to boost its generics drugs business, its new CEO said on Wednesday.

      Malvinder Singh, who took over the job at India's leading drugmaker last week, said he hoped a deal might be clinched in 2006, adding the U.S. market was a key priority.

      "We are actively looking at some targets today. My intent would be to look at concluding something (this year), but it must be a strategic fit that adds value," he told Reuters on the sidelines of the World Economic Forum annual meeting in Davos.

      "Clearly, in America we need to gain critical size," the chief executive added.

      "Our U.S. business today is around $350 million (a year). I think it is quite feasible to look at the same size through acquisition." Ranbaxy, which had worldwide sales of $1.2 billion in 2005, has ambitions to reach $2 billion in 2007 and then $5 billion by 2012 to become one of the world's top five generic drug companies.

      The generic drugs industry has seen a wave of consolidation recently, spearheaded by market leaders Teva Pharmaceutical Industries Ltd and Sandoz, the generics arm of Novartis AG.

      Singh noted that generic drugs businesses had sold in the past year for between one and five times their annual sales.

      Around the world, cheap generic medicines are in a sweet spot as governments promote their use to cut costs and as more branded blockbuster drugs lose patent protection.

      But competition is fierce, leading to pressure on prices and encouraging companies to seek greater economies of scale.

      That took a heavy toll on Ranbaxy in 2005, when profits fell 63 per cent and its shares lost 42 per cent due to falling prices in the United States, patent battle setbacks and high legal and research costs.

      January 25, 2006


      Share this Article!

    Back to top^